Drugs News and Research

RSS

Recent release: News coverage of AIDS 2012

The NYU Development Research Institute blog features an AIDS 2012 "Conference Political Courage Meter" graphic, based on Google News hits on different search terms.

26 Jul 2012

Two Ottawa researchers take innovative approaches to improve virus-based cancer therapy

Two Ottawa researchers are taking innovative approaches to improving virus-based cancer therapy with new funding from the Canadian Cancer Society.

26 Jul 2012

ZOLOFT holds promise against cryptococcal meningitis

New research conducted by biologists at Texas A&M University suggests that ZOLOFT, one of the most widely prescribed antidepressants in the world, also packs a potential preventative bonus - potent mechanisms capable of inhibiting deadly fungal infections.

26 Jul 2012

NIDA announces 2012 recipient of Avant-Garde Award for Medications Development

Dr. Gary R. Matyas has been selected the 2012 recipient of the NIDA Avant-Garde Award for Medications Development. Matyas proposes to develop an effective, safe and easily manufactured combination anti-heroin/HIV vaccine that could treat heroin addiction while at the same time prevent HIV infection in those receiving the vaccine.

26 Jul 2012

Malaria misdiagnosis: an interview with Dr Toby Leslie

Malaria is caused by a multi-staged parasite which is transmitted by the bite of infected female anopheles mosquitoes. It affects millions of people and kills more than 500,000 people throughout the world every year.

26 Jul 2012

Bio-Path initiates enrollment in fourth cohort of Liposomal Grb-2 Phase I trial for blood cancers

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has begun enrolling patients into the fourth dosage cohort in its Phase I clinical trial of its lead product candidate, BP-100.1.01 (Liposomal Grb-2), which is being evaluated as a systemic treatment for blood cancers including acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS).

26 Jul 2012

Combination of two stress hormones shuts down brain activity for goal-directed behaviour

Cognition psychologists at the Ruhr-Universit-t together with colleagues from the University Hospital Bergmannsheil (Prof. Dr. Martin Tegenthoff) have discovered why stressed persons are more likely to lapse back into habits than to behave goal-directed. The team of PD Dr. Lars Schwabe and Prof. Dr. Oliver Wolf from the Institute for Cognitive Neuroscience have mimicked a stress situation in the body using drugs.

26 Jul 2012

BD Hyflow needle essential for patient comfort and device integration

BD Medical, a segment of BD, today announced the launch of the BD Hyflow™ needle, a unique 27-gauge thin-wall needle designed for use with BD's prefillable syringe systems.

From BD (Becton, Dickinson and Company) 26 Jul 2012

FDA grants priority review to GSK’s Promacta sNDA for treatment of thrombocytopenia

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has been granted priority review from the US Food and Drug Administration for the supplemental new drug application for Promacta to treat thrombocytopenia in adult patients with chronic hepatitis C virus (HCV) infection.

26 Jul 2012

AHAF announces glaucoma and macular degeneration research grants

The American Health Assistance Foundation, a nonprofit organization with a history of funding breakthrough research on age-related vision diseases, announced today that it has awarded 21 new grants totaling $2.1 million to scientists worldwide who are studying glaucoma and macular degeneration. The two conditions are the leading causes of irreversible blindness in the world.

26 Jul 2012

CytRx commences aldoxorubicin plus doxorubicin Phase 1b trial in advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 1b clinical trial to determine the maximum tolerated dose and to evaluate preliminary efficacy of aldoxorubicin (formerly INNO-206) administered in combination with the commonly used chemotherapeutic agent doxorubicin in patients with advanced solid tumors who have failed other therapies.

26 Jul 2012

Malaria commonly misdiagnosed and mistreated in Afghanistan

Findings published in the BMJ suggest that malaria is being significantly misdiagnosed in Afghanistan, with many patients with fever alone being given antimalarial drugs and antibiotics despite having negative laboratory results for the disease.

25 Jul 2012

Reprieve for intraoperative nitrous oxide

A large analysis challenges the view that intraoperative nitrous oxide use should be avoided.

25 Jul 2012

NIH grants aim at creating 3-D tissue chips to help identify drug safety signals

Seventeen National Institutes of Health grants are aimed at creating 3-D chips with living cells and tissues that accurately model the structure and function of human organs such as the lung, liver and heart. Once developed, these tissue chips will be tested with compounds known to be safe or toxic in humans to help identify the most reliable drug safety signals - ultimately advancing research to help predict the safety of potential drugs in a faster, more cost-effective way.

25 Jul 2012

MASL protein from plant's seeds may halt spread of melanoma

An international team of scientists led by Gary Goldberg, PhD, of the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine (UMDNJ-SOM), has found that a protein from the seeds of a plant used for centuries in traditional medicines may be able to halt the spread of melanoma, a lethal form of skin cancer.

25 Jul 2012

Community health campaigns reduce incidence of HIV virus levels in rural Uganda

Population-wide levels of HIV virus dropped substantially between 2011 and May 2012 in a rural part of southwestern Uganda, the site of two community health campaigns led by doctors at the University of California, San Francisco (UCSF), San Francisco General Hospital and Trauma Center (SFGH) and Makerere University in Kampala, Uganda.

25 Jul 2012

Drug resistance increasing in parts of Africa, report shows

"Resistance to AIDS drugs, a problem that has been widely feared over the last decade, is growing in parts of Africa but should not hamper the life-saving drug rollout, researchers reported on Monday" in a study published in the Lancet, Agence France-Presse reports.

25 Jul 2012

New combination therapy for TB shows promise in Phase II study

"Results from a groundbreaking trial of three drugs given in combination -- one of them completely new and one not yet licensed for this use -- killed more than 99 percent of patients' [tuberculosis (TB)] bacteria after two weeks of treatment," and the combination "appears to be equally effective on drug-resistant TB," the Guardian reports.

25 Jul 2012

New NIAID grant to support development of topical microbicide gel for HIV and HSV-2 infections

A new grant from the National Institute of Allergy and Infectious Diseases (NIAID) will support the development of a topical microbicide gel for drug delivery. The innovative gel formulation will be a combination therapy against human immunodeficiency virus (HIV) and herpes simplex virus type 2 (HSV-2) infections in women.

25 Jul 2012

Malaria misdiagnosis in parts of Asia

Substantial overdiagnosis and mistreatment of malaria is evident in south and central Asia, warns a study published on bmj.com today.

25 Jul 2012

Drugs News and Research

Recent release: News coverage of AIDS 2012

Two Ottawa researchers take innovative approaches to improve virus-based cancer therapy

ZOLOFT holds promise against cryptococcal meningitis

NIDA announces 2012 recipient of Avant-Garde Award for Medications Development

Malaria misdiagnosis: an interview with Dr Toby Leslie

Bio-Path initiates enrollment in fourth cohort of Liposomal Grb-2 Phase I trial for blood cancers

Combination of two stress hormones shuts down brain activity for goal-directed behaviour

BD Hyflow needle essential for patient comfort and device integration

FDA grants priority review to GSK’s Promacta sNDA for treatment of thrombocytopenia

AHAF announces glaucoma and macular degeneration research grants

CytRx commences aldoxorubicin plus doxorubicin Phase 1b trial in advanced solid tumors

Malaria commonly misdiagnosed and mistreated in Afghanistan

Reprieve for intraoperative nitrous oxide

NIH grants aim at creating 3-D tissue chips to help identify drug safety signals

MASL protein from plant's seeds may halt spread of melanoma

Community health campaigns reduce incidence of HIV virus levels in rural Uganda

Drug resistance increasing in parts of Africa, report shows

New combination therapy for TB shows promise in Phase II study

New NIAID grant to support development of topical microbicide gel for HIV and HSV-2 infections

Malaria misdiagnosis in parts of Asia

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News